Viknesh Vijayenthiran June 28, 2013 Comment Now! PSA Peugeot Citroën, led by the Peugeot family, may see control ceded to General Motors, according to the latest reports. The struggling French ...
At a median follow-up of 21.5 months, ADT plus apalutamide significantly prolonged median PSA progression-free survival compared with ADT monotherapy (24.9 vs 20.3 months; hazard ratio [HR], 0.52).
Durable disease control, safety, and tolerability of abiraterone acetate (AA) in advanced castration-resistant prostate cancer (CRPC). Background: Gonadotropin releasing-hormone (GnRH) blockers are a ...
Phase III studies have demonstrated the clinical benefit of adding neo-adjuvant androgen deprivation to radical radiotherapy for clinically localised prostate cancer. We have developed a nomogram to ...
Please provide your email address to receive an email when new articles are posted on . Although there are plenty of drugs to treat psoriatic arthritis, and plenty of studies about those drugs ...
The Peugeot family wants to retake majority control of PSA/Peugeot Citroen, the head of the family told Automotive News Europe. Owning more than 50 percent of capital would protect PSA from ...
PARIS/MILAN -- French shareholders in the planned merger of PSA and Fiat Chrysler are seeking reassurances that they will retain a numerical advantage on a combined board if CEO Carlos Tavares were to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback